10-Q: Journey Medical Corp Reports Q1 2025 Results, Launches Emrosi

Journey Medical Corp reports its Q1 2025 financial results, highlighting the commercial launch of Emrosi and a slight increase in total net product revenues compared to Q1 2024.

Summary

• Journey Medical Corporation reported a net loss of $4.1 million for the three months ended March 31, 2025, compared to a net loss of $10.4 million for the same period in 2024.
• Total net product revenues for Q1 2025 were $13.1 million, a slight increase from $13.0 million in Q1 2024.
• The company launched Emrosi in the U.S. during Q1 2025, generating $2.1 million in net product revenue.
• Selling, general, and administrative expenses increased by $2.2 million to $10.6 million, primarily due to activities related to the Emrosi launch.
• Research and development costs decreased significantly to nil, compared to $7.9 million in Q1 2024, due to the completion of Emrosi's pre-approval project expenses.
• The company had $21.1 million in cash and cash equivalents as of March 31, 2025, compared to $20.3 million at the end of 2024.
• The company issued 834,722 shares of common stock under its at-the-market offering program, generating net proceeds of $4.1 million.
• Substantial doubt exists about the company's ability to continue as a going concern for at least twelve months from the date of issuance of these financial statements.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is still operating at a loss and has concerns about its ability to continue as a going concern, the launch of Emrosi and the decrease in net loss compared to the previous year are positive developments. The need for potential future capital raises introduces some uncertainty.

Positives

• The launch of Emrosi contributed $2.1 million in revenue.
• The net loss decreased significantly compared to the same period last year.
• Research and development expenses decreased substantially.
• The company secured additional capital through an at-the-market offering.
• The company's cash position increased slightly from the end of 2024.

Negatives

• The company experienced a net loss of $4.1 million.
• There is substantial doubt about the company's ability to continue as a going concern.
• Accutane revenue decreased by $2.2 million due to market competition.
• The company is reliant on sales of its pharmaceutical products to fund its core operations.

Risks

• The company's products are subject to intense regulation and clinical testing.
• A substantial portion of sales derive from products without patent protection and subject to generic competition.
• The company operates in a heavily regulated industry.
• Revenue is dependent on sales of dermatology products.
• Competition could limit the commercial opportunity and profitability of products.
• The company relies on third parties for several aspects of its operations.
• The company depends on its ability to identify, develop, and acquire or in-license products.
• Clinical drug development is expensive, time-consuming, and uncertain.
• Competitors could develop and commercialize similar or identical products.
• The company faces risks related to the protection of intellectual property.
• The company's business and operations would suffer in the event of computer system failures or cyber-attacks.
• Major public health issues, epidemics, or pandemics could affect product revenues and clinical trials.
• The company may need to raise additional capital.
• Fortress controls a voting majority of the company's common stock.

Future Outlook

The company may seek to raise capital through debt or equity financings to expand its product portfolio and for other strategic initiatives.

Management Comments

• The company is commercializing Emrosi in the U.S. with its existing commercial team.
• The company regularly evaluates market conditions, its liquidity profile, and financing alternatives to enhance its capital structure.

Industry Context

The company operates in the competitive dermatology market, facing competition from both branded and generic products.

Comparison to Industry Standards

• The company's performance can be compared to other commercial-stage pharmaceutical companies focused on dermatology, such as Galderma, Bausch Health, and Sun Pharmaceutical.
• Journey Medical's reliance on debt financing and at-the-market offerings is a common strategy for smaller pharmaceutical companies to fund operations and product launches.
• The company's royalty obligations and milestone payments are typical in the pharmaceutical industry for licensed products.

Management Changes

Legal Proceedings

• To the company's knowledge, there are no legal proceedings pending against it, other than routine actions, administrative proceedings, and other actions not deemed material.

Related Party Transactions

• The company recorded related party expenses to Fortress of approximately $11,703 and $9,361 for the three-month periods ended March 31, 2025 and 2024, respectively.
• At March 31, 2025, 42.68% of all classes of the company's outstanding common stock was owned by Fortress.

Stakeholder Impact

• The company's financial performance and strategic decisions may impact shareholders, employees, customers, suppliers, and creditors.
• The launch of Emrosi may benefit patients with dermatological conditions.
• The company's ability to continue as a going concern could affect its relationships with stakeholders.

Next Steps

• The company will continue to commercialize Emrosi in the U.S.
• The company will continue to evaluate market conditions and financing alternatives.
• The company will monitor the performance of its existing product portfolio.

Key Dates

Keywords

Emrosi, Journey Medical, Financial Results, Dermatology, Pharmaceutical, Q1 2025, Revenue, Net Loss